Umpqua Bank Names Kent Grubaugh EVP of Wealth Management Division
May 15, 2017 12:31 pm UTC| Business
PORTLAND, Ore., May 15, 2017 -- Umpqua Bank, a subsidiary of Umpqua Holdings Corporation (NASDAQ:UMPQ), announced today that it has hired Kent Grubaugh to oversee the company’s wealth management division. In this role,...
Umpqua Bank Names Kent Grubaugh EVP of Wealth Management Division
May 15, 2017 12:31 pm UTC| Business
PORTLAND, Ore., May 15, 2017 -- Umpqua Bank, a subsidiary of Umpqua Holdings Corporation (NASDAQ:UMPQ), announced today that it has hired Kent Grubaugh to oversee the company’s wealth management division. In this role,...
Umpqua Bank Names Kent Grubaugh EVP of Wealth Management Division
May 15, 2017 12:32 pm UTC| Business
PORTLAND, Ore., May 15, 2017 -- Umpqua Bank, a subsidiary of Umpqua Holdings Corporation (NASDAQ:UMPQ), announced today that it has hired Kent Grubaugh to oversee the company’s wealth management division. In this role,...
CardConnect Payment Solutions Is Certified as Powered by SAP NetWeaver®
May 15, 2017 12:31 pm UTC| Business
KING OF PRUSSIA, Pa., May 15, 2017 -- CardConnect® (NASDAQ:CCN), a leader in payment processing and technology solutions, today announced that CardConnect Payment Solutions Version 1.0 for SAP® ERP, its comprehensive...
CardConnect Payment Solutions Is Certified as Powered by SAP NetWeaver®
May 15, 2017 12:31 pm UTC| Business
KING OF PRUSSIA, Pa., May 15, 2017 -- CardConnect® (NASDAQ:CCN), a leader in payment processing and technology solutions, today announced that CardConnect Payment Solutions Version 1.0 for SAP® ERP, its comprehensive...
May 15, 2017 12:31 pm UTC| Business
BURLINGAME, Calif., May 15, 2017 -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today...
May 15, 2017 12:31 pm UTC| Business
BURLINGAME, Calif., May 15, 2017 -- Corvus Pharmaceuticals, Inc. (Nasdaq:CRVS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, today...